Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | TEK | Q02763 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283719 | 0.94 | RET (0.41) | CNR2RETMAPK14CNR1MAPT | |
| SCHEMBL283889 | 0.91 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL283574 | 0.83 | RET (0.40) | CNR2RETMAPK14CNR1MAPT | |
| SCHEMBL283706 | 0.82 | NPSR1 (0.55) | MAPTNPSR1GAAP2RY14MAPK1 | |
| SCHEMBL288529 | 0.81 | P2RY14 (0.48) | CNR2MAPK14CNR1P2RY14 | |
| SCHEMBL283144 | 0.81 | P2RY14 (0.48) | CNR2MAPK14CNR1P2RY14 | |
| SCHEMBL283367 | 0.77 | CNR2 (0.60) | CNR2 | |
| SCHEMBL2813991 | 0.77 | CNR2 (0.46) | CNR2RETMAPK14CNR1MAPT | |
| SCHEMBL283602 | 0.71 | CNR2 (0.75) | CNR2 | |
| SCHEMBL283601 | 0.71 | CNR2 (0.75) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| CN-102216277-A | Substituted benzamides as cannabinoid receptor ligands | ABBOTT LAB | 2011-10-12 | — | — | CN | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885RET 704/4885MAPK14 2205/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885RET 704/4885MAPK14 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.